Jason Zweig, MD
Pulmonary Disease · Saint Louis, MONPI 1982068359
Payments from drug & device makers
Across 126 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$546
- Jazz Pharmaceuticals Inc.$480
- GSK$478
- Merck$309
- Inspire Medical Systems, Inc.$247
- Insmed, Inc.$235
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,19396%
- Education$1324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 14 | $546 |
| Jazz Pharmaceuticals Inc. | 8 | $480 |
| GSK | 37 | $478 |
| Merck | 5 | $309 |
| Inspire Medical Systems, Inc. | 2 | $247 |
| Insmed, Inc. | 15 | $235 |
| Regeneron Healthcare Solutions, Inc. | 8 | $208 |
| Sanofi | 6 | $144 |
| Actelion Pharmaceuticals US, Inc. | 1 | $126 |
| AstraZeneca | 7 | $114 |
| Axsome Therapeutics, Inc. | 5 | $88 |
| Philips North America LLC | 3 | $58 |
| Resmed Corp | 2 | $48 |
| Mylan Specialty L.p. | 2 | $35 |
| Amgen | 2 | $33 |
| Novartis | 1 | $24 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Fisher & Paykel Healthcare Inc | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,325 in reported general payments places this provider in the 55th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 49 | $732 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $287 |
| Prednisone | 12 | $11 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Saint Louis
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
- Daniel RosenbluthSaint Louis$903K
- Derek ByersSaint Louis$835K
- Jeffrey AtkinsonSaint Louis$604K
- James KringsSaint Louis$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.